Matches in Nanopublications for { ?s ?p "[These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP540294.RAu-CaTSisTyTvzGWHUxBEcLJ8KNV2Z-JWbBbjpc5gJ9M130_assertion description "[These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP540294.RAu-CaTSisTyTvzGWHUxBEcLJ8KNV2Z-JWbBbjpc5gJ9M130_provenance.
- assertion description "[These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP255432.RASWKmAV39xddEk0pD7xyfzJQXCAXeSj876j4KZ79Kma0130_assertion description "[These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP255432.RASWKmAV39xddEk0pD7xyfzJQXCAXeSj876j4KZ79Kma0130_provenance.
- NP910846.RAl_Yro_D5TXwDDhxMX9DIi_ipUO3oTLIc-jp7UlM73Uk130_assertion description "[These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910846.RAl_Yro_D5TXwDDhxMX9DIi_ipUO3oTLIc-jp7UlM73Uk130_provenance.
- NP862858.RAYUSt4LqppI6eQyZXLQF2xlxwglJAHfROSiNytchfmls130_assertion description "[These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP862858.RAYUSt4LqppI6eQyZXLQF2xlxwglJAHfROSiNytchfmls130_provenance.
- assertion description "[These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP570880.RAEmOp6qmk3WtnhzWf2evpYZar-1UFaUxYsRJNASYd-us130_assertion description "[These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP570880.RAEmOp6qmk3WtnhzWf2evpYZar-1UFaUxYsRJNASYd-us130_provenance.
- NP570881.RA1-c9s9B9KY9j-9wtYIT9iRSJdXBcrdxMA18DYBDkQCg130_assertion description "[These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP570881.RA1-c9s9B9KY9j-9wtYIT9iRSJdXBcrdxMA18DYBDkQCg130_provenance.